Combinatorial chemistry, screening, preclinical and clinical bioanalysis, analytical chemistry, manufacturing R&D and production quality control (QC) all have unique needs and workflows. One of the controversial challenges in selecting a LIMS in pharma is the wide diversity of laboratories in a company. We will also discuss some of the new trends in the capabilities of LIMS, and in the use of LIMS in the pharmaceutical enterprise. These include in-house developed systems, 'generic' laboratory information management systems (LIMS), and commercial off-the-shelf (COTS) solutions. If Services are being performed on a time and materials basis, any estimates providedīy Seller are for planning purposes only.This article will review the challenges facing pharmaceutical laboratories, and examine the three most common alternatives available to pharmaceutical companies evaluating laboratory informatics systems in the context of the above-mentioned challenges. Therefore, Seller cannot guarantee that it will be able to fulfill Customer’s orders. Manufacturer price changes, supplier price changes and errors in advertisements.Īll orders are subject to Product availability and the availability of Personnel to perform the Services. Products and Service offerings for reasons including, but not limited to,Ĭhanging market conditions, Product discontinuation, Product unavailability, We intend to support, not replace, the doctor-patient relationship.ĮPharma reserves the right to make adjustments to pricing, Please consult your healthcare professionalĪnd discuss all your queries related to any disease or medicine. Lab tests, medicines, all possible side effects, drug interactions, warnings, alerts, etc. This may not cover everything about particular health conditions, The information contained herein should NOT be used as a substitute for the advice of a qualified physician. Although we do not guarantee the accuracy and the completeness of the information that provided and here information is for informational purposes only. It may be necessary to interrupt treatment to avoid additive effects which would increase the risk of hypoglycaemia.ĮPharma sole intention is to ensure that its consumers get proper information as musch as possible. Consideration must be given to the potency and duration of action of the previous blood sugar lowering agent. Any dose increase should be in accordance with guideline given above in 'initial dose and dose titration'. When substituting Glimepiride for other such agents, the initial daily dose is 1 mg this applies even in changeover from maximum dose of other oral blood sugar lowering agents. A dose adjustment must also be considered whenever the patient's weight or life-styie changes, or other factors arise which cause an increased susceptibility to hypo or hyperglycaemia.Ĭhangeover from other oral antidiabetics to Glimepiride: There is no exact dosage relationship between Glimepiride and other oral blood sugar lowering agents. To avoid hypoglycaemia, timely dose reduction or cessation of Glimepiride therapy must be considered. Secondary dosage adjustment: As control of diabetes improves, sensitivity to insuiin increases therefore, Glimepiride requirement may fall as treatment proceeds. It is very important not to skip meals after taking the drug. This should be taken immediately before a substantial breakfast or if none is taken immediately before the first main meal. Normally, a single daily dose is sufficient. Any increase can be based on regular blood sugar monitoring, and should be gradual, i.e., at intervals of 1 to 2 weeks, and carried out stepwise, as follows: 1 mg -> 2 mg -> 3 mg -> 4 mg -> 6 mg.ĭose in patients with well controlled diabetes: the usual dose range in patients with well controlled diabetes is 1 to 4 mg daily.ĭistribution of doses: Timing and distribution of doses are decided by the physician, in consideration of the patient's current life-style. Initial dose and dose titration: the usual initial dose is 1 mg once daily, if necessary, the daily dose can be increased. Monitoring of glucose levels in blood and urine also serves to detect either primary or secondary failure of therapy. The initial and the maintenance doses are set based on the results of regular check of glucose in blood and urine. The dosage of Glimepiride must be the lowest which is sufficient to achieve the desired metabolic control. In principle, the dosage of Glimepiride is governed by the desired blood sugar level.
0 Comments
Leave a Reply. |